Zomedica CORP 8-K filings

Zomedica Corp. held its annual shareholder meeting on June 10, 2026, where directors were elected, auditors ratified, and bylaws amended, but executive compensation failed to gain advisory approval.

Zomedica achieved record first-quarter revenue of $8.8 million, marking 35% year-over-year growth and its 21st consecutive quarter of record revenue.

Zomedica Corp. announced record fourth-quarter revenue of $10.5 million and full-year 2025 revenue of $32.0 million, marking 17% annual growth and its 20th consecutive quarter of year-over-year revenue increase.

Zomedica Corp. reported its highest-ever quarterly revenue of $8.1 million, a 16% increase year-over-year, driven by strong diagnostic and new development services growth, alongside a 67% gross margin and $54.4 million in liquidity.

Zomedica Corp. announced strong second quarter 2025 financial results, with revenue increasing 14% year-over-year to $7.0 million, driven by robust growth in diagnostic and therapeutic product sales.

Zomedica Corp. shareholders approved the election of directors and ratification of auditors but delivered a non-binding advisory vote against executive compensation at their annual meeting on June 10, 2025.

Zomedica reports a 4% increase in revenue to $6.5 million for Q1 2025, driven by strong consumable sales and international growth, while maintaining a robust 68% gross margin.

Zomedica Corp. announces the resignation of Chief Financial Officer Scott Jordan, effective April 25, 2025, with Vice President of Finance and Corporate Controller Michael Zuehlke assuming operational responsibility for accounting and finance matters until a replacement is found.

Zomedica announces record revenue of $7.9 million for the fourth quarter and $27.3 million for the full year 2024, driven by strong growth in its Diagnostics segment and a 70% gross margin.

Zomedica Corp. will transition to the OTCQB Venture Market after being delisted from the NYSE American due to noncompliance with listing standards regarding low share price.

Zomedica Corp. has appointed Scott Jordan as its new Chief Financial Officer, effective January 1, 2025, bringing over 30 years of experience in the life sciences and diagnostics industries.

Zomedica Corp. has entered into a new lease agreement for its headquarters, relocating to 1101 Technology Drive, Ann Arbor, effective February 1, 2025.

Zomedica's third quarter 2024 financial results show a 10% revenue increase to $7 million, driven by strong growth in both diagnostics and therapeutic device segments.

Zomedica achieved record revenue of $25.2 million in 2023, a 33% increase year-over-year, driven by strong performance in both its diagnostics and therapeutic devices segments.

Zomedica Corp. announces the resignation of its Chief Financial Officer, Peter Donato, effective August 15, 2024, with a consulting agreement in place for transition support.

Zomedica Corp. held its annual meeting on June 6, 2024, where shareholders elected all director nominees and ratified the appointment of Grant Thornton LLP as the independent auditor, but did not approve the executive compensation proposal.

Zomedica's first quarter 2024 revenue reached a record $6.3 million, a 14% increase year-over-year, driven by growth in both therapeutic devices and diagnostics segments.

Zomedica reports record annual revenue of $25.2 million for 2023, a 33% increase year-over-year, driven by strong growth in both its diagnostics and therapeutic devices segments.

Zomedica is in ongoing discussions with the NYSE American to address non-compliance with listing standards after a proposed reverse stock split was rejected by shareholders.

Zomedica's shareholders voted against a proposed 80-for-1 reverse stock split at a special meeting held on February 28, 2024.